Nanogels are promising carriers for the delivery of anti-cancer drugs for cancer therapy. We report in this study on a Janus nanogel system formed by mixing a prodrug of Taxol (PEGylated Taxol) and a copolymer of PLGA-PEG-PLGA. The Janus nanogels have good stability over months in aqueous solutions and the freeze-dried powder of nanogels can be re-dispersed instantly in aqueous solutions. The Janus nanogels show an enhanced inhibition effect on tumor growth in a mice breast cancer model probably due to the enhanced uptake of the nano-sized materials by the EPR effect. What is more, the nanogels can also serve as physical carriers to co-deliver other anti-cancer drugs such as doxorubicin to further improve the anti-cancer efficacy. The results obtained from H&E staining and TUNEL assay also support the observation of tumor growth inhibition. These results suggest the potential of this novel delivery system for cancer therapy.
Introduction
In order to solve the shortcomings of most anticancer drugs (e.g., low solubility, side effects to normal cells, fast blood clearance, etc.), 1 several drug delivery systems have been explored including liposomes, 2 block co-polymers, 3 dendrimers, 4 organic and inorganic nanoparticles, 5 vesicles, 6 nanogels, 7 and hydrogels (polymeric hydrogels 8 and molecular hydrogels 9 ). These drug carriers not only can enhance the water solubility of hydrophobic drugs, 10 but also have the ability to specically target tumor cells by ligand-receptor interaction or passive targeting via the tumors' enhanced permeability and retention (EPR) effect.
11 Our lab focuses on the development of molecular hydrogels of hydrophobic anti-cancer drugs as selfdelivery systems. 12 We recently reported a molecular hydrogel mainly formed by Taxol itself through an ester bond hydrolysis process that could inhibit the growth of tumors. 13 However, the gels exhibited a fast clearance property and only showed tumor inhibition effects for the rst 6 days probably due to weak mechanical property of the molecular hydrogel.
The strategy of incorporation of polymer additives could mechanically reinforce molecular hydrogels.
14 Therefore, we opted to mix a thermo-gelling polymeric hydrogel system of PLGA-PEG-PLGA with a pro-drug of Taxol, PEGylated Taxol. We thought that PEGylated Taxol could undergo ester bond hydrolysis to release Taxol and rstly form a molecular hydrogel at room temperature, and the copolymer of PLGA-PEG-PLGA could then form a polymeric hydrogel with good mechanical property post injection into the body at 37 C. However, we could not observe the ester bond hydrolysis of PEGylated Taxol and the formation of molecular hydrogels, but the co-assembly of the copolymer and PEGylated Taxol and the formation of Janus nanogels were observed. Nanogels are promising carriers for many therapeutic agents and may target tumor tissues via the EPR effect. 15 Our Janus nanogels may not only deliver the prodrug of Taxol, which is a component for the formation of Janus nanogels, but also serve as a physical carrier to encapsulate other drugs. We therefore evaluated the in vivo tumor inhibition effects of Janus nanogels themselves or in combination of other anti-cancer drugs (e.g. doxorubicin).
Materials and method

Preparation of the nanogel
2 g of PLGA-PEG-PLGA was dissolved in 20 mL of ddH 2 O. Sodium carbonate was added to adjust the nal pH to around 7.4. 20 mg of PEGylated Taxol was then added to 1 mL of the above solution to form the nanogels (the nal pH value was 7.4).
TEM image and DLS measurement of the nanogels
The morphology of the nanogel was characterized by transmission electron microscopy (TEM). In brief, a carbon lm coated copper grid was dipped in the nanogel solution, and then it was placed in a desiccator overnight. The TEM images were recorded on a MODEL H-800 electron microscope operating at an acceleration voltage of 100 kV. The size of the nanogel was also obtained on a ZetaPALS + BI-90Plus system.
In vivo pharmacokinetics analysis
All experiments of animal study were performed in compliance with the relevant laws and institutional guidelines of Nankai University, and the institutional committee had approved the experiments. Pharmacokinetics of TaxolÒ and nanogels was investigated using a female Balb/c mouse of 18-20 g body weight. Intravenous administration was conducted through the animal's ophthalmic vein at a dose of 10 mg paclitaxel per kg. Blood samples were collected at indicated time points. The treatment method was according to the reference. Briey, 500 mL of blood samples were collected in a heparinized tube at designated time intervals. The sample plasma was harvested by centrifugation at 1500g for 10 min. Liquid-liquid extraction was performed to separate Taxol from plasma. An LCMS-20AD (Shimadzu) system was used to determine the concentration of Taxol in the sample. Pharmacokinetic parameters were processed by soware PKSolver. 
In vivo evaluation of antitumor activity
Preparation of doxorubicin (Dox) loaded nanogel
2 mg or 4 mg of Dox was dissolved in 1 mL of the nanogel solution. Sodium carbonate was then added to adjust the nal pH value of the solution to around 7.4. To conrm the homogeneity of this solution, centrifugation at 12 000 rad s À1 was used. No precipitate was observed aer 10 min centrifugation.
Haematoxylin/eosin (H&E) and in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
The mice were sacriced and tumors were collected and xed for 24 h in 4% PBS buffered paraformaldehyde. Aer gradient sugar dehydration, tissue sections (6 mm) were stained with haematoxylin/eosin (H&E). At least six frozen sections from each animal were used for H&E staining. In brief, the slides were washed with ddH 2 O for 5 minutes and then stained with hematoxylin for 10 minutes. Aer washing with ddH 2 O for 5 minutes, the slides were dipped in HCl-ethanol solution for one second and then washed with water immediately. Aer staining with eosin for 3 seconds, the slides were washed with water for 5 minutes and the following solutions were used for dehydration: 70%, 80%, 90%, and 95% ethanol respectively. Aer dipping into toluene for 5 minutes, they were dried and mounted. TUNEL assay was performed using a FragELÔ DNA fragment detection kit (colorimetric-TdT enzyme method) according to the manufacturer's protocol (EMD chemicals Inc., Darmstadt, Germany). Briey, tumor sections were transferred onto the glass slides, then deparaffinized with xylene and ethanol, and washed in 1Â TBS. Aer 100 mL of proteinase K (20 mg mL À1 ) in tris buffer (pH 8.0) was added onto the slides, they were incubated for 20 min at room temperature. A 3% H 2 O 2 aqueous solution was added to inactivate endogenous peroxidase at room temperature, and then the slides were washed with PBS, treated with terminal deoxynucleotidyl transferase (TdT enzyme) at 37 C for 90 min, and washed again with PBS.
Exposed 3 0 -OH ends of the breakage DNA fragment in the apoptotic cells were labeled with biotin-labeled deoxynucleotides. The tumor sections on slides were nally incubated at room temperature for 30 min with a streptavidin-horseradish peroxidase conjugate, during which diaminobenzidine reacted with the labeled sample to generate an insoluble brown DAB signal with shading from blue-green to greenish tan signifying non-apoptotic cells.
Statistical analysis
Tumor model data are represented as mean AE SEM. The tumor growth curve was compared and analyzed using the two-way analysis of variance test (ANOVA), performed by GraphPad Prism 5.01 for Windows. *p < 0.05, **p < 0.01 and ***p < 0.001 were used throughout the article to show statistical signicance.
3 Results and discussion
Formation of nanogel
We designed and synthesized a PEG (2000)-Taxol conjugate (PEGylated Taxol in Scheme S1 †) as the precursor of Taxol.
3c
Similar to our previous observation, the PEGylated Taxol could also release Taxol and form a molecular hydrogel by ester bond hydrolysis (Fig. 1B) . The minimum gelation concentration (MGC) of PEGylated Taxol was about 1.4 wt%. The mechanical properties of a gel formed from 2.0 wt% of PEGylated Taxol were weak, with an elasticity (G 0 ) value of about 40 Pa (Fig. S3 †) . We opted to improve the mechanical properties of the hydrogel because our previous molecular hydrogels of Taxol with the mode of intra-tumor injection showed fast clearance within 6 days probably due to the weak mechanical properties of molecular hydrogels. We chose a thermo-gelling system of copolymer PLGA-PEG-PLGA, which was an excellent biomedical material for controlled drug delivery due to its amphiphilic and temperature sensitive properties. 16 As shown in Fig. 1A , a water solution containing 20 wt% of the copolymer would change into a gel at temperatures above 28 C. We supposed that the incorporation of the thermo-gelling system would mechanically reinforce the molecular hydrogels formed from the solution of PEGylated Taxol in Fig. 1B . Therefore, the mixed and double network hydrogel system could be injected into or around tumors for long term delivery of Taxol. Surprisingly, we only obtained solutions when mixing solutions of the copolymer (20 wt%) and PEGylated Taxol (2.0 wt%) even upon incubation at room temperature for more than one week. For PLGA-PEG-PLGA thermogels, the three dimensional network of the gel was formed by physical interaction/entanglement of PLGA segments at high temperature. When mixing the copolymer and PEGylated Taxol, due to the formation of a certain kind of nanostructure, PLGA segments served as the core of them and therefore could not form a three dimensional network for hydrogelation. Based on the LC-MS analysis, there was no ester bond hydrolysis of PEGylated Taxol. The mixed solution could not change to a gel at 37 C either. In order to form a thermo-gel of the copolymer with 2.0 wt% of PEGylated Taxol, the concentration of the copolymer should be higher than 32 wt%, and we only observed slightly opaque solutions when the concentration of the copolymer was lower than 32 wt%. As shown in Fig. 1D , higher concentrations of the copolymer were needed to form thermo-gels when using higher concentrations of PEGylated Taxol. While mixing the copolymer, Taxol, and PEG (2000), the mixture could form gels at temperatures over 28 C. We therefore realized that the PEG on PEGylated Taxol might interact with the PEG-segment on the copolymer to form a certain kind of nanostructure, which would prevent the ester bond hydrolysis and the release of Taxol.
Morphology and size distribution of the nanogel
We then used transmission electron microscopy (TEM) to characterize the morphology of the nanostructures in the solution. As shown in Fig. 2A , Janus nanogels with the size of 80-200 nm were observed. As shown in Fig. 2B , we proposed that our Janus gel relied on the co-assembly of PLAG-PEG-PLGA and PEG-Taxol. The PLGA and Taxol were in the hydrophobic core of the Janus particle and hydrophilic PEG formed the shell to stabilize the particle in aqueous solutions. We also obtained a TEM image of solutions of the copolymer (20 wt%) and PEGylated Taxol (20 wt%) and we only observed dark dots in the nanoparticle of PEGylated Taxol (Fig. S5 †) . These observations indicated that the dark dots in the Janus nanogels in Fig. 2A were the aggregates of Taxol. Based on dynamic light scattering (DLS) measurement (Fig. S2 †) , there were two kinds of size distributions of the nanogels (one about 20 and the other about 250 nm). This nanogel system was very stable and there was no precipitate or ester bond hydrolysis of PEGylated Taxol observed for up to one month. Unlike the copolymer itself which needed sonication to help to dissolve in aqueous solutions at a concentration of 20 wt%, the powder of the freeze-dried nanogel could be re-dispersed in aqueous solutions instantly at concentrations lower than 30 wt% (total weight percentage of the two components). This ready re-dispersion property was crucial for its storage and practical application.
In vivo evaluation of antitumor efficacy and in vivo pharmacokinetics analysis
The antitumor activity of Janus nanogels was investigated in vivo using a 4T-1 orthotopic xenogra model of breast cancer in Balb/c mice. The following groups were evaluated in the experiment, including a PBS vehicle control, two dosages of TaxolÒ at 10 mg kg À1 Â 4 and 10 mg kg at the dosage of 60 mg kg À1 (53.6% of tumor size relative to the PBS control at day 14). Higher dosages of nanogels possessed slightly higher tumor growth inhibition property and the relative tumor size was 30.8, 25.7, and 20.9% for the PBS control at day 14 for groups treated with nanogels at the dosage of 20, 40, and 60 mg kg À1 , respectively. These results clearly indicated that nanogels had good efficiency to inhibit tumor growth probably due to the EPR effect which would enhance tumor uptake of the nanogels. 11a Meanwhile the weight of the mice was also recorded as in Fig. S6 , † the mice treated with nanogels at three dosages showed no obvious body weight loss compared with the PBS control group, while those treated with TaxolÒ at a high dosage of 60 mg kg À1 exhibited an obvious body weight decrease probably due to the existence of an organic solvent in the clinically used TaxolÒ. These observations suggested the good biocompatibility of our nanogels. In vivo pharmacokinetics of paclitaxel formulated in a nanogel or in TaxolÒ was investigated by using normal mice at a dose of 10 mg kg À1 . As shown in Fig. 3C , the nanogel exhibited signicant pharmacokinetic advantages versus TaxolÒ. The drug was rapidly cleared from plasma aer intracellular administration of TaxolÒ. Aer 10 hours, the concentration of Taxol in plasma was below the minimum therapeutic effective level (43 ng mL À1 ). 17 Instead, the concentration of Taxol in nanogel formulation showed a constant plasma concentration over the experimental period of 50 h. The results clearly demonstrated the long lasting property of our nanogel system versus TaxolÒ.
Co-delivery of Dox and its in vivo anti-tumor activity
Synergistic combination of two or more drugs attracts more and more attention as a promising strategy to achieve better anticancer effects and overcome the undesirable toxicity and other side effects during chemotherapy.
18 Therefore, it is signicant to explore drug delivery systems that could encapsulate two or more drugs in one nanocarrier and co-deliver them to tumors. Recently the Shen group reported novel high drug loading multifunctional nanocapsules formed by the prodrug of OEG-CPT. 5b These nanocapsules can load Dox for intracellular drug delivery. Our Janus nanogel consisted of a prodrug of Taxol and a copolymer could also serve as a carrier to physically entrap other anti-cancer drugs such as doxorubicin (Dox). As shown in Fig. 4B and C, Dox could not dissolve well in the aqueous solution at the pH of 7.4 (1 mg mL À1 , Fig. 4B ), while the addition of 2 mg mL À1 of Dox to our nanogel system would lead to a homogeneous solution (Fig. 4C) . From the TEM image (Fig. 4D) , the incorporation of Dox slightly decreased the size of Janus nanogels to 50-150 nm.
We then tested the in vivo activity of this co-delivery system for tumor inhibition. Five groups of mice with tumors were tested including those treated with a PBS vehicle control, 10 mg kg À1 TaxolÒ Â 2, 10 mg kg À1 Â 2 of nanogel, 2 mg kg À1 Â 2 of Dox, and 10 mg kg À1 nanogel plus 2 mg kg À1 Dox Â 2 (all were i.v. injected and administered every other day). Aer 16 days of the treatment (Fig. 4E) , the group of nanogels with Dox showed a remarkable reduction in tumor size relative to the PBS control and other treatment groups with a single kind of drug. The results indicated that our nanogels could be carriers for the codelivery of other anti-cancer drugs and the combination therapy would have better efficiency to inhibit tumor growth.
In vivo analysis of the histological characteristics and TUNEL analyses
We also performed the histological and immunohistochemical studies to demonstrate the excellent therapeutic effect of Janus nanogels. In H&E staining (Fig. S8A1-A6 †), cells with scattering dots (broken nuclei) were abnormal ones (apoptotic or necrosis Fig. 5A1 , the PBS control group did not show an apoptotic region while other groups treated with drug obviously exhibited many apoptotic cells. Overall, the treatment groups with Janus nanogels and nanogel loaded Dox showed more apoptotic and nectrotic cells than other groups. The results indicated that our Janus nanogels could signi-cantly inhibit tumor growth by inducing tumor cell apoptosis or necrosis. The better therapeutic effect of nanogels was probably due to the enhanced uptake of nanogels by tumor tissue through the EPR effect.
Conclusion
In summary, we successfully prepared a novel kind of Janus nanogel system consisting of copolymer PLGA-PEG-PLGA and a prodrug of Taxol (PEGylated Taxol). This Janus nanogel could not only inhibit the growth of tumor more efficiently than the clinically used TaxolÒ, but also serve as a vesicle to transport other anticancer drugs to tumors. This novel formulation of Taxol could be freeze-dried and stored as powder, which could re-dissolve instantly upon the addition of aqueous solutions such as PBS buffer solution. These observations suggested the great potential of our Janus nanogel for cancer therapy. 10 mg kg À1 Â 2 PEG-Taxol; 2 mg kg À1 Â 2 Dox; 10 mg kg À1 nanogel; 10 mg kg À1 nanogel containing 2 mg kg À1 Â 2 Dox. Brown and green stains indicated apoptotic and normal cells, respectively, in TUNEL analysis. Scale bars represent 100 mm.
